Update about Oralair® as a treatment for grass pollen allergic rhinitis
| Autor: | L. Klimek, R. Brehler, R. Mösges, P. Demoly, J. Mullol, D. Y. Wang, R. E. O’Hehir, A. Didier, M. Kopp, C. Bos, E. Karagiannis |
|---|---|
| Přispěvatelé: | Centre for Rhinology and Allergy, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), University of Cologne, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Médecine de précision par intégration de données et inférence causale (PREMEDICAL), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), National University of Singapore (NUS), Monash Central Clinical School [Melbourne] (CCS), Faculty of Medicine, Nursing and Health Sciences - Monash university [Victoria], Monash university-Monash university, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Universität zu Lübeck = University of Lübeck [Lübeck], Stallergenes Greer (France, Antony) |
| Rok vydání: | 2022 |
| Předmět: |
MESH: Allergens
Immunology Administration Sublingual MESH: Plant Extracts Poaceae sublingual immunotherapy MESH: Poaceae Humans Immunology and Allergy [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology MESH: Treatment Outcome Pharmacology MESH: Humans MESH: Antigens Plant Plant Extracts allergic rhinoconjunctivitis MESH: Quality of Life 5-Grass pollen tablet [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy Allergens Antigens Plant asthma Rhinitis Allergic Treatment Outcome MESH: Administration Sublingual MESH: Pollen Quality of Life allergen immunotherapy MESH: Rhinitis Allergic MESH: Tablets Pollen Tablets MESH: Sublingual Immunotherapy |
| Zdroj: | Human Vaccines & Immunotherapeutics Human Vaccines & Immunotherapeutics, 2022, 18 (5), pp.2066424. ⟨10.1080/21645515.2022.2066424⟩ |
| ISSN: | 2164-554X 2164-5515 |
| DOI: | 10.1080/21645515.2022.2066424 |
| Popis: | International audience; Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|